Effect of Growth Hormone in Metabolic Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00307411|
Recruitment Status : Unknown
Verified March 2006 by Chinese University of Hong Kong.
Recruitment status was: Not yet recruiting
First Posted : March 28, 2006
Last Update Posted : April 4, 2006
|Condition or disease||Intervention/treatment||Phase|
|Metabolic Syndrome||Drug: Growth hormone||Phase 4|
Metabolic syndrome, a constellation of glucose intolerance, hypertension, dyslipidemia, obesity, pro-inflammatory and prothrombotic state culminating to development of premature cardiovascular diseases is a serious public health problem with significant impact on life expectancy, societal productivity and quality of life of those afflicted with it. Insulin resistance has been proposed as the key linking factor for the metabolic syndrome. Although the underlying mechanism for the development of insulin resistance, diabetes and metabolic syndrome is not fully understood, increasing evidence suggests that neurohormonal dysregulation plays a pivotal role in causing this growing health hazard. In our previous study of 307 middle-aged men, low insulin-like growth factor (IGF)-1 level was independently associated with insulin resistance and metabolic syndrome, especially amongst those with positive family history of diabetes. Replacement with growth hormone has been shown by other researchers to reduce body fat and improve metabolic profiles in patients with adult growth hormone deficiency and type 2 diabetes.
We hypothesize that treatment with growth hormone can lead to reduction of body fat, insulin resistance and cardiovascular risk factors in men with metabolic syndrome. This will be a 12-month prospective, randomized, double-blind, placebo-controlled study using growth hormone treatment in middle-aged men with metabolic syndrome. The primary outcome measure will be body fat distribution, including changes in visceral and mesenteric fat, whereas secondary outcome measure will be insulin sensitivity, and tertiary outcome will be variable parameters of metabolic syndrome.
The results of this study will have important impact on the treatment of patients with metabolic syndrome, and our understanding of the role of growth hormone in the pathogenesis of insulin resistance, diabetes and metabolic syndrome.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||32 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome|
|Study Start Date :||August 2006|
|Study Completion Date :||July 2007|
- Change in percentage of body fat from baseline.
- Examine the percentage change from baseline in insulin sensitivity, various indices of metabolic syndrome of growth hormone treatment will be compared to placebo arm.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00307411
|Contact: Alice PS Kong, M.B.,Ch.B.||852-2632 firstname.lastname@example.org|
|Prince of Wales Hospital, The Chinese University of Hong Kong||Not yet recruiting|
|Hong Kong SAR, China|
|Contact: Alice PS Kong, M.B.,Ch.B. 852-2632 3123 email@example.com|
|Principal Investigator: Alice PS Kong, M.B.,Ch.B.|
|Principal Investigator:||Alice PS Kong, M.B.,Ch.B.||Chinese University of Hong Kong|